The Black ALZ Brain Study seeks to recruit 1,000 North Texas-based residents, ages 50 and older, to research why African Americans are at a greater biological risk of Alzheimer’s disease. Long-term, the goal is to develop new treatments that can prevent the deadly disease. The first-of-its kind research is co-led by Dr. Sid O’Bryant and Dr. Leigh Johnson. O’Bryant is the Executive Director of the Institute for Translational Research, which is dedicated to precision medicine in Alzheimer’s disease and other neurodegenerative diseases, including Down syndrome, Lewy Body disease, Parkinson’s disease, and traumatic brain injury, among others. Johnson is the Associate Director of the Institute for Translational Research and an associate professor in the Departments of Pharmacology and Neuroscience and Family Medicine.